FEDRATINIB

Brand name:

• Inrebic®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD

Condition/indication:
(therapeutic use)

• Myelofibrosis (MF)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to listing (Matters arising from the minutes)

Comment:

--

Other PBAC consideration:

• FEDRATINIB
• FEDRATINIB

Submission received for:

May 2026 PBAC meeting

Opportunity for consumer comment:

Open 30/07/2025 and close 24/09/2025 (see PBS Website)

PBAC meeting:

Held on 08/05/2026

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

Awaiting lodgement from pharmaceutical company

5Lodgement of required documentation:

Has not yet commenced

6Agreement to listing arrangements:

Has not yet commenced

7Government processes:

Has not yet commenced

8Medicine listed on the PBS:

Has not yet occurred